Human IFN-α Antibody - Rontalizumab Biosimilar

Anti-human IFN alpha - Rontalizumab biosimilar - CAS #948570-30-7

Binding of Anti-hIFN-α Rontalizumab

Anti-hIFN-α-hIgG1 is a biosimilar antibody of Rontalizumab, a therapeutic antibody that targets interferon alpha (IFN-α). This monoclonal antibody (mAb) blocks the interaction of IFN-α with its receptor. Rontalizumab has been clinically evaluated as an immunosuppressive agent for the treatment of systemic lupus erythematosus (SLE).

 More details

Anti-hIFN-α-hIgG1 comprises the variable region of Rontalizumab and the human IgG1 constant region of Rontalizumab with high effector functions. 

This antibody can be used with HEK-Blue™ IFN-α/β cells for screening and neutralization assays to block recombinant human IFN-α-induced signaling (see figure).

Key features

• Potent and specific neutralization activity against hIFN-α2
• Reacts with hIFN-α1, hIFN-α2, hIFN-α5, hIFN-α8, hIFN-α14, hIFN-α16, hIFN-α17, and hIFN-α21
• Weakly reacts with hIFN-α4 and IFN-α10
• Does not react with hIFN-α6 or hIFN-α7
• Each lot is functionally tested and validated.
• The complete sequence of the antibody construct was verified.
• The absence of endotoxins is determined using the EndotoxDetect™ assay.

All InvivoGen products are for internal research use only, and not for human or veterinary use.

Figures

Dose-dependent inhibition of HEK-Blue™ IFN-α/β cell response using Anti-IFN-α-IgG. A serial dilution of Anti-IFN-α-IgG monoclonal antibody (mAb) was incubated with 500 U/ml of recombinant human IFN-α2b for 30 minutes prior to the addition of the HEK-Blue™ IFN-α/β cells. After overnight incubation, the ISGF3 response was determined using QUANTI‑Blue™ Solution, a SEAP detection reagent. Data are presented as percentage of neutralization (mean ± SEM).

Specifications

Application: Neutralization assay, ELISA

Isotype:  Human IgG1, kappa

Recommended isotype control: Human IgG1

Target: Human IFN-α2. Note: This mAb also reacts with human IFN-α1, IFN-α5, IFN-α8, IFN-α14, IFN-α16, IFN-α17, and IFN-α21. It very weakly reacts with human IFN-α4 and IFN-α10. It does not react with IFN-α6 or IFN-α7 (In-house data).

Species reactivity: Human

Clone: Rontalizumab

Cas number: 948570-30-7

Source: CHO cells 

Production: Animal-free

Purification: Protein A

Molecular weight: ~ 150 kDa

Physical form: Lyophilized

Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative: Azide-free

Reconstitution buffer: Sterile water (not provided)

Purity: ≥ 95 %

Quality control: Each lot is functionally tested and validated.

Contents

• 200 µg of purified Anti-hIFN-α-IgG antibody, provided azide-free and lyophilized.

 The product is shipped at room temperature.

 Store lyophilized antibody at -20 °C.

 Lyophilized product is stable for at least 1 year.

 Avoid repeated freeze-thaw cycles.

Details

Rontalizumab background

Rontalizumab (aka rhuMAb interferon-alpha) is a therapeutic, humanized monoclonal antibody (mAb) that targets the human interferon-alpha (IFN-α) cytokine subtypes [1, 2]. By binding to IFN-α, Rontalizumab prevents it from interacting with its receptor (IFNAR) on the surface of immune cells, thus inhibiting the downstream inflammatory response. Rontalizumab has been clinically evaluated as an immunosuppressive agent for the treatment of systemic lupus erythematosus (SLE) [1-3]. 

References:

1. McBride JM, et al. 2012. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 64(11):3666-76.
2. Kalunian KC, et al., 2016. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. (2016) 75:196–202.
3. Jones, S.A. and Morand, E.F., 2024. Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned. Drugs. 84(6):625-635.